{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+w%2Fv+NaCL+Saline",
    "query": {
      "intervention": "0.9% w/v NaCL Saline"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 37,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+w%2Fv+NaCL+Saline&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T19:06:08.913Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00912496",
      "title": "Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "MF-59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "A/Anhui/05",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 637,
      "start_date": "2010-06",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-05-14",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00912496"
    },
    {
      "nct_id": "NCT03041025",
      "title": "Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "GSK2330811",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2017-06-05",
      "completion_date": "2020-07-07",
      "has_results": true,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03041025"
    },
    {
      "nct_id": "NCT01544283",
      "title": "Pain Patch Versus Injections in the Treatment of Pain Associated With Shoulder Impingement Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Shoulder Pain"
      ],
      "interventions": [
        {
          "name": "Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Injury Care Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2012-03",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 1,
      "location_summary": "Boise, Idaho",
      "locations": [
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01544283"
    },
    {
      "nct_id": "NCT02799472",
      "title": "Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "MTX",
          "type": "DRUG"
        },
        {
          "name": "Folic (or folinic) acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2016-06-15",
      "completion_date": "2017-10-30",
      "has_results": true,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 8,
      "location_summary": "El Cajon, California • Fort Lauderdale, Florida • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799472"
    },
    {
      "nct_id": "NCT05002998",
      "title": "TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Teprotumumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 313,
      "start_date": "2021-09-16",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 7,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 4 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05002998"
    },
    {
      "nct_id": "NCT04584684",
      "title": "Mouth Rinses for Inactivation of COVID-19",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Covid19",
        "Coronavirus Infection",
        "SARS-CoV-2 Infection"
      ],
      "interventions": [
        {
          "name": "0.9% w/v NaCL Saline",
          "type": "OTHER"
        },
        {
          "name": "1.5% w/v Hydrogen Peroxide",
          "type": "DRUG"
        },
        {
          "name": "0.12% Chlorohexidine Gluconate",
          "type": "DRUG"
        },
        {
          "name": "27% Ethanol plus essential oils",
          "type": "DRUG"
        },
        {
          "name": "0.5% w/v Povidone-iodide",
          "type": "DRUG"
        },
        {
          "name": "0.075% Cetylpyridinium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 128,
      "start_date": "2020-12-18",
      "completion_date": "2021-10-21",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04584684"
    },
    {
      "nct_id": "NCT05567783",
      "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza A"
      ],
      "interventions": [
        {
          "name": "VIR-2482 (450 mg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VIR-2482 (1200 mg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 2977,
      "start_date": "2022-10-30",
      "completion_date": "2023-08-31",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 51,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 45 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Pomona",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567783"
    },
    {
      "nct_id": "NCT07285213",
      "title": "Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clostridioides Difficile Infection"
      ],
      "interventions": [
        {
          "name": "AZD5148",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 230,
      "start_date": "2025-12-10",
      "completion_date": "2028-01-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 43,
      "location_summary": "Phoenix, Arizona • Chula Vista, California • Sacramento, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285213"
    },
    {
      "nct_id": "NCT03173625",
      "title": "A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "AC-076 for s.c. administration",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Viatris Innovation GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 72,
      "start_date": "2016-11-29",
      "completion_date": "2017-04-15",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173625"
    },
    {
      "nct_id": "NCT05159050",
      "title": "Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peritoneal Carcinomatosis"
      ],
      "interventions": [
        {
          "name": "Paclitaxel-loaded tumor penetrating microparticles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carlos Chan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2022-04-26",
      "completion_date": "2025-12-09",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-10-04T19:06:08.913Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05159050"
    }
  ]
}